Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 18:9:4323-36.
doi: 10.2147/OTT.S106944. eCollection 2016.

Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance

Affiliations
Review

Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance

Maria Pyszniak et al. Onco Targets Ther. .

Abstract

The endocannabinoid system (ECS) comprises cannabinoid receptors (CBs), endogenous cannabinoids, and enzymes responsible for their synthesis, transport, and degradation of (endo)cannabinoids. To date, two CBs, CB1 and CB2, have been characterized; however, orphan G-protein-coupled receptor GPR55 has been suggested to be the third putative CB. Several different types of cancer present abnormal expression of CBs, as well as other components of ECS, and this has been shown to correlate with the clinical outcome. Although most effects of (endo)cannabinoids are mediated through stimulation of classical CBs, they also interact with several molecules, either prosurvival or proapoptotic molecules. It should be noted that the mode of action of exogenous cannabinoids differs significantly from that of endocannabinoid and results from the studies on their activity both in vivo and in vitro could not be easily compared. This review highlights the main signaling pathways involved in the antitumor activity of cannabinoids and the influence of their activation on cancer cell biology. We also discuss changes in the expression pattern of the ECS in various cancer types that have an impact on disease progression and patient survival. A growing amount of experimental data imply possible exploitation of cannabinoids in cancer therapy.

Keywords: cancer; cannabinoid receptor; cannabinoids; cell signaling; delta-9-tetrahy-drocannabinol.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Influence of synthetic, plant-derived, and endogenous cannabinoids on signaling molecules leading to tumor growth inhibition and/or cancer cell death. Notes: ↑, increased; ↓, decreased. Abbreviations: ER, endoplasmic reticulum; ROS, reactive oxygen species; AMPK, 5′AMP-activated protein kinase; Ang, Angiopoietin; AEA, N-arachidonoylethanolamide; CBD, Cannabidiol; CXCL, Chemokine (c-x-c motif) ligand; EGFR, Epidermal growth factor receptor; ERK, Extracellular signal-regulated kinase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase GEM, Gemcitabine; GRP, Glucose-regulated protein; Met-F-AEA, 2-methyl-20-F-anandamide; MMP, Matrix metalloproteinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PCNA, Proliferating cell nuclear antigen; STAT, Signal transducer and activator of transcription; TIMP, Tissue inhibitor matrix metalloproteinases; THC, Tetrahydrocannabinol; TRB, Tribblespseudokinase; TRPM, Transient receptor potential cation channel subfamily M member; uPA, Urokinase-type plasminogen activator; VEGF, Vascular endothelial growth factor; VEGFR, Vascular endothelial growth factor receptor.

References

    1. Pisanti S, Picardi P, D’Alessandro A, Laezza C, Bifulco M. The endocannabinoid signaling system in cancer. Trends Pharmacol Sci. 2013;34:273–282. - PubMed
    1. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605–613. - PubMed
    1. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65. - PubMed
    1. Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther. 2010;126(3):301–313. - PMC - PubMed
    1. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745–755. - PubMed

LinkOut - more resources